Selection of biologics for patients with metastatic colorectal cancer: the role of predictive markers
Author:
Publisher
Informa UK Limited
Subject
Gastroenterology,Hepatology
Link
http://www.tandfonline.com/doi/pdf/10.1586/17474124.2015.1001743
Reference24 articles.
1. Improved Survival in Metastatic Colorectal Cancer Is Associated With Adoption of Hepatic Resection and Improved Chemotherapy
2. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial
3. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial
4. Intermittent chemotherapy plus either intermittent or continuous cetuximab for first-line treatment of patients with KRAS wild-type advanced colorectal cancer (COIN-B): a randomised phase 2 trial
5. The Efficacy and Safety of Panitumumab Administered Concomitantly With FOLFIRI or Irinotecan in Second-Line Therapy for Metastatic Colorectal Cancer: The Secondary Analysis From STEPP (Skin Toxicity Evaluation Protocol With Panitumumab) by KRAS Status
Cited by 10 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. METASTATİK KOLOREKTAL KANSERLİ HASTALARIN EGFR YA DA VEGF İNHİBİTÖRÜ KULLANIM DURUMLARINA GÖRE KLİNİK ÖZELLİKLERİNİN İNCELENMESİ;Kocatepe Tıp Dergisi;2023-10-09
2. Could the concomitant use of beta blockers with bevacizumab improve survival in metastatic colon cancer?;European Journal of Clinical Pharmacology;2023-02-07
3. PTPRT and PTPRD Deleterious Mutations and Deletion Predict Bevacizumab Resistance in Metastatic Colorectal Cancer Patients;Cancers;2018-09-06
4. Bevacizumab in Colorectal Cancer: Current Role in Treatment and the Potential of Biosimilars;Targeted Oncology;2017-08-11
5. Molecular subtypes of metastatic colorectal cancer are associated with patient response to irinotecan-based therapies;European Journal of Cancer;2017-05
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3